224 related articles for article (PubMed ID: 37849818)
1. Risk factors of breast cancer recurrence in pathologic complete response achieved by patients following neoadjuvant chemotherapy: a single-center retrospective study.
Choi JY; Woen D; Jang SY; Lee H; Shin DS; Kwak Y; Lee H; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
Front Oncol; 2023; 13():1230310. PubMed ID: 37849818
[TBL] [Abstract][Full Text] [Related]
2. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy.
Asaoka M; Narui K; Suganuma N; Chishima T; Yamada A; Sugae S; Kawai S; Uenaka N; Teraoka S; Miyahara K; Kawate T; Sato E; Nagao T; Matsubara Y; Gandhi S; Takabe K; Ishikawa T
Eur J Surg Oncol; 2019 Dec; 45(12):2289-2294. PubMed ID: 31787153
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors and prognostic value of pathologic complete response of ipsilateral supraclavicular lymph nodes in breast cancer after neoadjuvant chemotherapy.
Zhu J; Jiao D; Guo X; Qiao J; Ma Y; Zhang J; Chen H; Xiao H; Yang Y; Lu Z; Liu Z
Ann Transl Med; 2019 Nov; 7(22):666. PubMed ID: 31930067
[TBL] [Abstract][Full Text] [Related]
6. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
Pang J; Wang S; Liao L; Liu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival.
Houvenaeghel G; de Nonneville A; Cohen M; Sabiani L; Buttarelli M; Charaffe E; Jalaguier A; Bannier M; Tallet A; Viret F; Gonçalves A
Cancer Med; 2024 Feb; 13(3):e6930. PubMed ID: 38327130
[TBL] [Abstract][Full Text] [Related]
8. Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer.
Zhang GC; Zhang YF; Xu FP; Qian XK; Guo ZB; Ren CY; Yao M
Curr Oncol; 2013 Jun; 20(3):e180-92. PubMed ID: 23737688
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer.
Zhang X; Wang D; Liu Z; Wang Z; Li Q; Xu H; Zhang B; Liu T; Jin F
Quant Imaging Med Surg; 2020 Jan; 10(1):197-210. PubMed ID: 31956542
[TBL] [Abstract][Full Text] [Related]
10. Distinct Prognosis of Minimal Residual Disease According to Breast Cancer Subtype in Patients with Breast or Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy.
Go J; Ahn JH; Park JM; Choi SB; Kim JY; Park HS; Kim SI; Park BW; Park S
Ann Surg Oncol; 2023 Nov; 30(12):7060-7068. PubMed ID: 37537485
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period.
Choi M; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
J Pathol Transl Med; 2017 Jan; 51(1):69-78. PubMed ID: 28013533
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
13. Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy.
Xie LY; Wang K; Chen HL; Shi YX; Zhang YQ; Lin HY; Liang YK; Xiao YS; Wu ZY; Yuan ZY; Qiu SQ
Front Oncol; 2022; 12():860475. PubMed ID: 35515127
[TBL] [Abstract][Full Text] [Related]
14. Discrepancy of Breast and Axillary Pathologic Complete Response and Outcomes in Different Subtypes of Node-positive Breast Cancer after Neoadjuvant Chemotherapy.
Chen SC; Yu CC; Chang HK; Lin YC; Lo YF; Shen SC; Kuo WL; Tsai HP; Chou HH; Chu CH; Shen WC; Wu RC; Ueng SH; Huang YT
J Cancer; 2021; 12(17):5365-5374. PubMed ID: 34335953
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies.
Poterala JE; Havighurst T; Braun Wisinski K
Clin Breast Cancer; 2022 Aug; 22(6):611-618. PubMed ID: 35676188
[TBL] [Abstract][Full Text] [Related]
16. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
17. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
[TBL] [Abstract][Full Text] [Related]
18. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
19. Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy.
Choi HJ; Ryu JM; Kim I; Nam SJ; Kim SW; Yu J; Lee JE; Lee SK
Breast Cancer Res Treat; 2019 Aug; 176(3):591-596. PubMed ID: 31065874
[TBL] [Abstract][Full Text] [Related]
20. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
